Efficacy of corticosteroid therapy for HTLV-1-associated myelopathy: a randomized controlled trial (HAMLET-P)

Detalhes bibliográficos
Autor(a) principal: Yamauchi, Junji
Data de Publicação: 2022
Outros Autores: Tanabe, Kenichiro, Sato, Tomoo, Nakagawa, Masanori, Matsuura, Eiji, Tsuboi, Yoshio, Tamaki, Keiko, Sakima, Hirokuni, Ishihara, Satoshi, Ohta, Yuki, Matsumoto, Naoki, Kono, Kenichi, Yagishita, Naoko, Araya, Natsumi, Takahashi, Katsunori, Kunitomo, Yasuo, Nagasaka, Misako, Reilly, Ariella Coler, Hasegawa, Yasuhiro, Araujo, Abelardo, Jacobson, Steven, Grassi, Maria Fernanda Rios, Castro, Bernardo Galvão, Bland, Martin, Taylor, Graham P, Martin, Fabiola, Yamano, Yoshihisa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/51603
Resumo: Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Frontier Medicine. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Neurology. Kyoto Prefectural University of Medicine Graduate School of Medical Science. Kyoto. Department of Neurology and Geriatrics. Kagoshima University Graduate School of Medical and Dental Sciences. Kagoshima, Japan. Department of Neurology. Fukuoka University. Fukuoka, Japan. Department of Neurology. Fukuoka University. Fukuoka, Japan. Department of Cardiovascular Medicine. Nephrology and Neurology. Graduate School of Medicine. University of the Ryukyus, Okinawa, Japan. Department of Cardiovascular Medicine. Nephrology and Neurology. Graduate School of Medicine. University of the Ryukyus, Okinawa, Japan. Department of Pharmacology. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Pharmacology. St. Marianna University School of Medicine. Kawasaki, Japan. Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe. Kobe, Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki. Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki. Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Advanced Medical Innovation. St. Marianna University Graduate School of Medicine. Kawasaki, Japan / Division of Hematology and Oncology. Department of Medicine. University of California Irvine School of Medicine. Irvine, CA, USA. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Department of Internal Medicine. Division of Bone and Mineral Diseases. Washington University School of Medicine. St. Louis, MO, USA. Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. SHIN-YURIGAOKA General Hospital. Kanagawa, Japan. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Neuroinfecções. Rio de Janeiro, RJ, Brasil. Viral immunology Section. Neuroimmunology Branch. National Institute of Neurological Disorders and Stroke. National Institutes of Health. Bethesda, MD, USA. Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. Department of Health Sciences. Seebohm Rowntree Building. University of York. York , UK. Section of Virology. Department of Infectious Disease. Imperial College London. London, UK. School of Public Health. Faculty of Medicine. University of Queensland. 266 Herston Road. Herston, Australia. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan.
id CRUZ_dc9fdbfce77bdc5c840a09cd9a53a48d
oai_identifier_str oai:www.arca.fiocruz.br:icict/51603
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Yamauchi, JunjiTanabe, KenichiroSato, TomooNakagawa, MasanoriMatsuura, EijiTsuboi, YoshioTamaki, KeikoSakima, HirokuniIshihara, SatoshiOhta, YukiMatsumoto, NaokiKono, KenichiYagishita, NaokoAraya, NatsumiTakahashi, KatsunoriKunitomo, YasuoNagasaka, MisakoReilly, Ariella ColerHasegawa, YasuhiroAraujo, AbelardoJacobson, StevenGrassi, Maria Fernanda RiosCastro, Bernardo GalvãoBland, MartinTaylor, Graham PMartin, FabiolaYamano, Yoshihisa2022-03-07T19:44:43Z2022-03-07T19:44:43Z2022Yamauchi, Junji et al. Efficacy of corticosteroid therapy for htlv-1-associated myelopathy: a randomized controlled trial (HAMLET-P). Viruses, v. 14, n. 136, p. 1-17, 2022.1999-4915https://www.arca.fiocruz.br/handle/icict/51603doi.org/10.3390/v14010136Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Frontier Medicine. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Neurology. Kyoto Prefectural University of Medicine Graduate School of Medical Science. Kyoto. Department of Neurology and Geriatrics. Kagoshima University Graduate School of Medical and Dental Sciences. Kagoshima, Japan. Department of Neurology. Fukuoka University. Fukuoka, Japan. Department of Neurology. Fukuoka University. Fukuoka, Japan. Department of Cardiovascular Medicine. Nephrology and Neurology. Graduate School of Medicine. University of the Ryukyus, Okinawa, Japan. Department of Cardiovascular Medicine. Nephrology and Neurology. Graduate School of Medicine. University of the Ryukyus, Okinawa, Japan. Department of Pharmacology. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Pharmacology. St. Marianna University School of Medicine. Kawasaki, Japan. Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe. Kobe, Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki. Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki. Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Advanced Medical Innovation. St. Marianna University Graduate School of Medicine. Kawasaki, Japan / Division of Hematology and Oncology. Department of Medicine. University of California Irvine School of Medicine. Irvine, CA, USA. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Department of Internal Medicine. Division of Bone and Mineral Diseases. Washington University School of Medicine. St. Louis, MO, USA. Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. SHIN-YURIGAOKA General Hospital. Kanagawa, Japan. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Neuroinfecções. Rio de Janeiro, RJ, Brasil. Viral immunology Section. Neuroimmunology Branch. National Institute of Neurological Disorders and Stroke. National Institutes of Health. Bethesda, MD, USA. Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. Department of Health Sciences. Seebohm Rowntree Building. University of York. York , UK. Section of Virology. Department of Infectious Disease. Imperial College London. London, UK. School of Public Health. Faculty of Medicine. University of Queensland. 266 Herston Road. Herston, Australia. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan.Practical Research Project for Rare/Intractable Diseases of the Japan Agency for Medical Research and Development. Ministry of Health, Labour and Welfare of Japan."Múltipla ver em Notas"Corticosteroids are most commonly used to treat HTLV-1-associated myelopathy (HAM); however, their clinical efficacy has not been tested in randomized clinical trials. This randomized controlled trial included 8 and 30 HAM patients with rapidly and slowly progressing walking disabilities, respectively. Rapid progressors were assigned (1:1) to receive or not receive a 3-day course of intravenous methylprednisolone in addition to oral prednisolone therapy. Meanwhile, slow progressors were assigned (1:1) to receive oral prednisolone or placebo. The primary outcomes were a composite of ≥1-grade improvement in the Osame Motor Disability Score or ≥30% improvement in the 10 m walking time (10 mWT) at week 2 for rapid progressors and changes from baseline in 10 mWT at week 24 for slow progressors. In the rapid progressor trial, all four patients with but only one of four without intravenous methylprednisolone achieved the primary outcome (p = 0.14). In the slow progressor trial, the median changes in 10 mWT were −13.8% (95% CI: −20.1–−7.1; p < 0.001) and −6.0% (95% CI: −12.8–1.3; p = 0.10) with prednisolone and placebo, respectively (p for between-group difference = 0.12). Whereas statistical significance was not reached for the primary endpoints, the overall data indicated the benefit of corticosteroid therapy.engMDPIVírus Linfotrópico T Tipo 1 HumanoPrednisolonaMetilprednisolonaEnsaio Clínico Controlado AleatórioHuman T-lymphotropic virus 1PrednisoloneMethylprednisoloneRandomized Controlled TrialVirus Linfotrópico T Tipo 1 HumanoPrednisolonaMetilprednisolonaEnsayo Clínico Controlado AleatorioVirus T-lymphotrope humain de type 1PrednisoloneMéthylprednisoloneEssai contrôlé randomiséEfficacy of corticosteroid therapy for HTLV-1-associated myelopathy: a randomized controlled trial (HAMLET-P)info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/51603/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALYamauchi, J. Efficacy....pdfYamauchi, J. Efficacy....pdfapplication/pdf1473614https://www.arca.fiocruz.br/bitstream/icict/51603/2/Yamauchi%2c%20J.%20Efficacy....pdf4a406fc71db98892c3f9976c942b5934MD52icict/516032023-03-15 14:33:13.019oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:33:13Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Efficacy of corticosteroid therapy for HTLV-1-associated myelopathy: a randomized controlled trial (HAMLET-P)
title Efficacy of corticosteroid therapy for HTLV-1-associated myelopathy: a randomized controlled trial (HAMLET-P)
spellingShingle Efficacy of corticosteroid therapy for HTLV-1-associated myelopathy: a randomized controlled trial (HAMLET-P)
Yamauchi, Junji
Vírus Linfotrópico T Tipo 1 Humano
Prednisolona
Metilprednisolona
Ensaio Clínico Controlado Aleatório
Human T-lymphotropic virus 1
Prednisolone
Methylprednisolone
Randomized Controlled Trial
Virus Linfotrópico T Tipo 1 Humano
Prednisolona
Metilprednisolona
Ensayo Clínico Controlado Aleatorio
Virus T-lymphotrope humain de type 1
Prednisolone
Méthylprednisolone
Essai contrôlé randomisé
title_short Efficacy of corticosteroid therapy for HTLV-1-associated myelopathy: a randomized controlled trial (HAMLET-P)
title_full Efficacy of corticosteroid therapy for HTLV-1-associated myelopathy: a randomized controlled trial (HAMLET-P)
title_fullStr Efficacy of corticosteroid therapy for HTLV-1-associated myelopathy: a randomized controlled trial (HAMLET-P)
title_full_unstemmed Efficacy of corticosteroid therapy for HTLV-1-associated myelopathy: a randomized controlled trial (HAMLET-P)
title_sort Efficacy of corticosteroid therapy for HTLV-1-associated myelopathy: a randomized controlled trial (HAMLET-P)
author Yamauchi, Junji
author_facet Yamauchi, Junji
Tanabe, Kenichiro
Sato, Tomoo
Nakagawa, Masanori
Matsuura, Eiji
Tsuboi, Yoshio
Tamaki, Keiko
Sakima, Hirokuni
Ishihara, Satoshi
Ohta, Yuki
Matsumoto, Naoki
Kono, Kenichi
Yagishita, Naoko
Araya, Natsumi
Takahashi, Katsunori
Kunitomo, Yasuo
Nagasaka, Misako
Reilly, Ariella Coler
Hasegawa, Yasuhiro
Araujo, Abelardo
Jacobson, Steven
Grassi, Maria Fernanda Rios
Castro, Bernardo Galvão
Bland, Martin
Taylor, Graham P
Martin, Fabiola
Yamano, Yoshihisa
author_role author
author2 Tanabe, Kenichiro
Sato, Tomoo
Nakagawa, Masanori
Matsuura, Eiji
Tsuboi, Yoshio
Tamaki, Keiko
Sakima, Hirokuni
Ishihara, Satoshi
Ohta, Yuki
Matsumoto, Naoki
Kono, Kenichi
Yagishita, Naoko
Araya, Natsumi
Takahashi, Katsunori
Kunitomo, Yasuo
Nagasaka, Misako
Reilly, Ariella Coler
Hasegawa, Yasuhiro
Araujo, Abelardo
Jacobson, Steven
Grassi, Maria Fernanda Rios
Castro, Bernardo Galvão
Bland, Martin
Taylor, Graham P
Martin, Fabiola
Yamano, Yoshihisa
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Yamauchi, Junji
Tanabe, Kenichiro
Sato, Tomoo
Nakagawa, Masanori
Matsuura, Eiji
Tsuboi, Yoshio
Tamaki, Keiko
Sakima, Hirokuni
Ishihara, Satoshi
Ohta, Yuki
Matsumoto, Naoki
Kono, Kenichi
Yagishita, Naoko
Araya, Natsumi
Takahashi, Katsunori
Kunitomo, Yasuo
Nagasaka, Misako
Reilly, Ariella Coler
Hasegawa, Yasuhiro
Araujo, Abelardo
Jacobson, Steven
Grassi, Maria Fernanda Rios
Castro, Bernardo Galvão
Bland, Martin
Taylor, Graham P
Martin, Fabiola
Yamano, Yoshihisa
dc.subject.other.pt_BR.fl_str_mv Vírus Linfotrópico T Tipo 1 Humano
Prednisolona
Metilprednisolona
Ensaio Clínico Controlado Aleatório
topic Vírus Linfotrópico T Tipo 1 Humano
Prednisolona
Metilprednisolona
Ensaio Clínico Controlado Aleatório
Human T-lymphotropic virus 1
Prednisolone
Methylprednisolone
Randomized Controlled Trial
Virus Linfotrópico T Tipo 1 Humano
Prednisolona
Metilprednisolona
Ensayo Clínico Controlado Aleatorio
Virus T-lymphotrope humain de type 1
Prednisolone
Méthylprednisolone
Essai contrôlé randomisé
dc.subject.en.pt_BR.fl_str_mv Human T-lymphotropic virus 1
Prednisolone
Methylprednisolone
Randomized Controlled Trial
dc.subject.es.pt_BR.fl_str_mv Virus Linfotrópico T Tipo 1 Humano
Prednisolona
Metilprednisolona
Ensayo Clínico Controlado Aleatorio
dc.subject.fr.pt_BR.fl_str_mv Virus T-lymphotrope humain de type 1
Prednisolone
Méthylprednisolone
Essai contrôlé randomisé
description Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Frontier Medicine. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Neurology. Kyoto Prefectural University of Medicine Graduate School of Medical Science. Kyoto. Department of Neurology and Geriatrics. Kagoshima University Graduate School of Medical and Dental Sciences. Kagoshima, Japan. Department of Neurology. Fukuoka University. Fukuoka, Japan. Department of Neurology. Fukuoka University. Fukuoka, Japan. Department of Cardiovascular Medicine. Nephrology and Neurology. Graduate School of Medicine. University of the Ryukyus, Okinawa, Japan. Department of Cardiovascular Medicine. Nephrology and Neurology. Graduate School of Medicine. University of the Ryukyus, Okinawa, Japan. Department of Pharmacology. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Pharmacology. St. Marianna University School of Medicine. Kawasaki, Japan. Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe. Kobe, Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki. Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki. Japan. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan. Department of Advanced Medical Innovation. St. Marianna University Graduate School of Medicine. Kawasaki, Japan / Division of Hematology and Oncology. Department of Medicine. University of California Irvine School of Medicine. Irvine, CA, USA. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Department of Internal Medicine. Division of Bone and Mineral Diseases. Washington University School of Medicine. St. Louis, MO, USA. Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. SHIN-YURIGAOKA General Hospital. Kanagawa, Japan. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Neuroinfecções. Rio de Janeiro, RJ, Brasil. Viral immunology Section. Neuroimmunology Branch. National Institute of Neurological Disorders and Stroke. National Institutes of Health. Bethesda, MD, USA. Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. Department of Health Sciences. Seebohm Rowntree Building. University of York. York , UK. Section of Virology. Department of Infectious Disease. Imperial College London. London, UK. School of Public Health. Faculty of Medicine. University of Queensland. 266 Herston Road. Herston, Australia. Department of Rare Diseases Research. Institute of Medical Science. St. Marianna University School of Medicine. Kawasaki, Japan / Division of Neurology. Department of Internal Medicine. St. Marianna University School of Medicine. Kawasaki, Japan.
publishDate 2022
dc.date.accessioned.fl_str_mv 2022-03-07T19:44:43Z
dc.date.available.fl_str_mv 2022-03-07T19:44:43Z
dc.date.issued.fl_str_mv 2022
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv Yamauchi, Junji et al. Efficacy of corticosteroid therapy for htlv-1-associated myelopathy: a randomized controlled trial (HAMLET-P). Viruses, v. 14, n. 136, p. 1-17, 2022.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/51603
dc.identifier.issn.pt_BR.fl_str_mv 1999-4915
dc.identifier.doi.none.fl_str_mv doi.org/10.3390/v14010136
identifier_str_mv Yamauchi, Junji et al. Efficacy of corticosteroid therapy for htlv-1-associated myelopathy: a randomized controlled trial (HAMLET-P). Viruses, v. 14, n. 136, p. 1-17, 2022.
1999-4915
doi.org/10.3390/v14010136
url https://www.arca.fiocruz.br/handle/icict/51603
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/51603/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/51603/2/Yamauchi%2c%20J.%20Efficacy....pdf
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
4a406fc71db98892c3f9976c942b5934
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324777190948864

Registros relacionados